Bioatla Inc (BCAB) Stock Analysis
Verdict: AVOID
Imminent Nasdaq delisting to OTC and under 2 months of cash runway make insolvency or severe equity dilution virtually guaranteed.
Investment score: 9/100
Analysis as of
Is Bioatla Inc stock worth reviewing? AI model thesis
The AI model assigns an AVOID rating on BioAtla Inc (BCAB). The company faces an imminent loss of its Nasdaq listing alongside a cash runway of under 2 months based on 2025 operating cash burn. Without substantial capital injection, equity holders face near-term wipeout risk.
7-factor investment score
- Valuation: 5/100 (weight 20%)
- Financial Health: 0/100 (weight 15%)
- Technical Momentum: 5/100 (weight 15%)
- Earnings Quality: 30/100 (weight 15%)
- Insider Sentiment: 10/100 (weight 10%)
- Analyst Consensus: 20/100 (weight 10%)
- Risk-Adjusted Return: 0/100 (weight 15%)
Bioatla Inc opportunities and risks
What speaks for BCAB
- Clinical pipeline progression for BA3011 and BA3021
What speaks against BCAB
- Imminent insolvency and bankruptcy filing risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| BCAB | n/a | 0.3x | n/a | -4.2% | -370.0% | -815.5% |
| CRIS | n/a | 0.7x | 0.1x | 99.3% | -490.3% | -1053.3% |
| GNPX | n/a | 0.0x | 0.8x | 0.0% | 0.0% | -839.8% |
| VCNX | n/a | 1.3x | n/a | 98.3% | -251.1% | -241.3% |
| MTNB | n/a | 0.0x | n/a | 0.0% | 0.0% | -501.1% |
| ENZC | n/a | 0.0x | n/a | 0.0% | 0.0% | 0.0% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -501.1% |
Frequently asked questions about Bioatla Inc (BCAB)
Is BCAB stock a good investment?
The cached TradeMates AI model rates Bioatla Inc as AVOID with an investment score of 9/100. The AI model assigns an AVOID rating on BioAtla Inc (BCAB). The company faces an imminent loss of its Nasdaq listing alongside a cash runway of under 2 months based on 2025 operating cash burn. Without substantial capital injection, equity holders face near-term wipeout risk. This is algorithmic model output, not personal investment advice.
Is BCAB stock a buy?
The TradeMates model verdict for BCAB is AVOID with an investment score of 9/100. Treat this as a model signal to review, not a personal buy recommendation.